Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug547 | Best Standard of Care + CARDIO Wiki | 1.00 |
| drug546 | Best Standard of Care Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.
Description: Proportion, Rate
Measure: Incidence of IgG against SARS-CoV-2 Time: one yearDescription: Titer
Measure: titration and evolution of humoral response (IgG) along first 12 months after having Covid-19 Time: 12 monthsDescription: Categoric Yes/Not
Measure: Reinfection of Covid-19 Time: one yearDescription: Rate
Measure: Mortality Time: 12 months after Covid-19Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports